Drug
L19il2 L19tnf
L19il2 L19tnf: highest development phase Phase 2, developed by Philogen S.p.A.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Philogen S.p.A.
Trials
| Drug | Phase | Indication |
|---|---|---|
| L19IL2/L19TNF NCT07228442 | Phase 2 | Locally Advanced Cutaneous Squamous Cell Carcinoma |
Latest
No recent events.
Follow L19il2 L19tnf on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.